6 I kliniske forsøg var forekomsten af parkinsonisme og dystoni hos olanzapin- behandlede patienter numerisk højere men ikke statistisk signifikant forskellig fra placebo.
6 In clinical trials, the incidence of parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.